See-Mode Technologies is a MedTech company based in Singapore and Australia that applies deep learning and computational modeling to medical images to help clinicians predict stroke and select optimal treatments. Its first product, AVA (Augmented Vascular Analysis), is commercially available and approved as a class B medical device by Singapore’s Health Sciences Authority, with CE and FDA approvals pending. The company is running clinical studies with major stroke centers and research institutes worldwide to build scientific evidence for its technology. See-Mode plans to use new funding to expand commercially into Europe and the United States in the coming year and to broaden partnerships with research institutions. It also intends to strengthen operations by at least doubling its team, hiring across product roles, and expanding R&D, engineering, sales, and business development capabilities. See-Mode was founded in 2017 by biomedical engineers Milad Mohammadzadeh and Sadaf Monajemi. The company’s core product is medical software that assists clinicians in interpreting ultrasound images and assessing patients’ blood flow patterns from CT scans or MRIs. It also enables detection of vulnerable plaques, a diagnostic capability previously inaccessible in many clinics. See-Mode counts the National University Hospital, Changi General Hospital, and the National Neuroscience Institute of Singapore as partners. The company plans to launch a clinical study with hospitals in the United States and Australia. Financially, See-Mode has just completed a seed financing round of US$1 million.

Total raised

$8M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2020